Skip to main content
SpringerLink
Log in

T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science

  • Chapter
  • First Online:
T-Cell Lymphomas

Part of the book series: Contemporary Hematology ((CH))

  • 1282 Accesses

Abstract

T-cell malignancies are neoplasms that arise from cells of the innate and adaptive immune system. They are rare in the Western hemisphere and more so in children and young adolescents. They exhibit tremendous clinical and molecular heterogeneity and can pose diagnostic and therapeutic challenges for the oncology community. The recent World Health Organization classification outlines over 20 distinct subtypes of T-cell malignancies. In this chapter we provide an in-depth overview of the state of the clinical and biological science of T-cell malignancies with a focus on the three most common subtypes, T lymphoblastic leukemia/lymphoma, and anaplastic large cell lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Borowitz MJ, Chan JKC. T lymphoblastic leukaemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 176–8.

    Google Scholar 

  2. Mature T- and NK-cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 270–319.

    Google Scholar 

  3. Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol. 2008;26:8–20.

    PubMed  CAS  Google Scholar 

  4. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91:735–46.

    PubMed  CAS  Google Scholar 

  5. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2006. p. 538–90.

    Google Scholar 

  6. Ballerini P, Landman-Parker J, Cayuela JM, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. Haematologica. 2008;93:1658–65.

    PubMed  Google Scholar 

  7. Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616–22.

    PubMed  Google Scholar 

  8. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896–904.

    PubMed  CAS  Google Scholar 

  9. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.

    PubMed  Google Scholar 

  10. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–41.

    PubMed  CAS  Google Scholar 

  11. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004;104:2690–6.

    PubMed  CAS  Google Scholar 

  12. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122–33.

    PubMed  CAS  Google Scholar 

  13. Uckun FM, Reaman G, Steinherez PG, et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children’s Cancer Group Study. Leuk Lymphoma. 1996;24:57–70.

    PubMed  CAS  Google Scholar 

  14. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115:110–7.

    PubMed  CAS  Google Scholar 

  15. Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol. 2006;24:5750–62.

    PubMed  Google Scholar 

  16. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group study CCG-1941. J Clin Oncol. 2006;24:3150–6.

    PubMed  Google Scholar 

  17. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children’s Oncology Group Study [corrected]. J Clin Oncol. 2008;26:3971–8.

    PubMed  CAS  Google Scholar 

  18. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol. 2005;23:3376–82.

    PubMed  CAS  Google Scholar 

  19. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310–22.

    PubMed  CAS  Google Scholar 

  20. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591–8.

    PubMed  CAS  Google Scholar 

  21. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52–8.

    PubMed  CAS  Google Scholar 

  22. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–8.

    PubMed  Google Scholar 

  23. Dunsmore K, Devidas M, Borowitz MJ, et al. Nelarabine in combination with intensive modified BFM AALL00P2: a pilot study for the treatment of high risk T-ALL a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:10002.

    Google Scholar 

  24. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–56.

    PubMed  CAS  Google Scholar 

  25. Satwani P, Sather H, Ozkaynak F, et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a children’s oncology group study report. Biol Blood Marrow Transplant. 2007;13:218–27.

    PubMed  CAS  Google Scholar 

  26. Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006;24:5742–9.

    PubMed  Google Scholar 

  27. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6.

    PubMed  CAS  Google Scholar 

  28. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71.

    PubMed  CAS  Google Scholar 

  29. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15:50–8.

    PubMed  CAS  Google Scholar 

  30. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007;110:278–86.

    PubMed  CAS  Google Scholar 

  31. Cullion K, Draheim KM, Hermance N, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood. 2009;113:6172–81.

    PubMed  CAS  Google Scholar 

  32. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle. 2008;7:965–70.

    PubMed  CAS  Google Scholar 

  33. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007;13:70–7.

    PubMed  CAS  Google Scholar 

  34. Cairo MS. Non-Hodgkin’s lymphoma and lymphoproliferative disorders in children. In: Carroll WL, Finlay J, editors. Cancer in children and adolescents. Sudbury: Jones and Bartlett Publishers; 2010. p. 217–34.

    Google Scholar 

  35. Cairo MS, Bradley MB. Lymphoma. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: Elsevier; 2007. p. 2123–6.

    Google Scholar 

  36. Cairo MS, Raetz E, Perkins SL. Non-Hodgkin’s lymphoma in children. In: Kufe DW, Bast RC, Hait WN, et al., editors. Cancer medicine. 7th ed. Hamilton, ON: BC Decker Inc.; 2005. p. 1962–76.

    Google Scholar 

  37. Burkhardt B, Moericke A, Klapper W, et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma. 2008;49:451–61.

    PubMed  CAS  Google Scholar 

  38. Raetz EA, Perkins SL, Bhojwani D, et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2006;47:130–40.

    PubMed  Google Scholar 

  39. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster Group. J Clin Oncol. 2009;27:3363–9.

    PubMed  Google Scholar 

  40. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416–21.

    PubMed  CAS  Google Scholar 

  41. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205–22.

    PubMed  CAS  Google Scholar 

  42. Link MP, Weinstein HJ. Malignant non-Hodgkin lymphomas in children. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2006. p. 722–47.

    Google Scholar 

  43. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med. 1997;337:1259–66.

    PubMed  CAS  Google Scholar 

  44. Patte C, Kalifa C, Flamant F, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20:105–13.

    PubMed  CAS  Google Scholar 

  45. Wollner N, Burchenal JH, Lieberman PH, Exelby P, D’Angio G, Murphy ML. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976;37:123–34.

    PubMed  CAS  Google Scholar 

  46. Pillon M, Piglione M, Garaventa A, et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of pediatric hematology and oncology. Pediatr Blood Cancer. 2009;53:953–9.

    PubMed  Google Scholar 

  47. Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24:491–9.

    PubMed  Google Scholar 

  48. Abromowitch M, Sposto R, Perkins S, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol. 2008;143:261–7.

    PubMed  CAS  Google Scholar 

  49. Abromowitch M, Termuhlen A, Lynch J, et al. High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971. Hematol Meeting Rep. 2009;3:33.

    Google Scholar 

  50. Uyttebroeck A, Suciu S, Laureys G, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44:840–6.

    PubMed  Google Scholar 

  51. Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23:1127–30.

    PubMed  CAS  Google Scholar 

  52. Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993;11:1024–32.

    PubMed  CAS  Google Scholar 

  53. Hartmann O, Pein F, Beaujean F, et al. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. J Clin Oncol. 1984;2:979–85.

    PubMed  CAS  Google Scholar 

  54. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95.

    PubMed  CAS  Google Scholar 

  55. Won SC, Han JW, Kwon SY, et al. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin’s lymphoma: a report from the Korean society of pediatric hematology-oncology. Ann Hematol. 2006;85:787–94.

    PubMed  Google Scholar 

  56. Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children’s Cancer Group Study CCG-5912. J Clin Oncol. 2001;19:2390–6.

    PubMed  CAS  Google Scholar 

  57. Kleiner S, Kirsch A, Schwaner I, et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone Marrow Transplant. 1997;20:953–9.

    PubMed  CAS  Google Scholar 

  58. Bureo E, Ortega JJ, Munoz A, et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin’s lymphoma. Spanish Working Party for bone marrow transplantation in children. Bone Marrow Transplant. 1995;15:353–9.

    PubMed  CAS  Google Scholar 

  59. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–53.

    PubMed  CAS  Google Scholar 

  60. Levine JE, Harris RE, Loberiza Jr FR, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003;101:2476–82.

    PubMed  CAS  Google Scholar 

  61. Smock KJ, Lim MS, Agarwal AM, et al. Expression of mTOR pathway proteins and notch1 in pediatric lymphoblastic lymphoma (LBL): a Children’s Oncology Group Report. Hematol Meeting Rep. 2009;3:38.

    Google Scholar 

  62. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006;108:2392–8.

    PubMed  CAS  Google Scholar 

  63. Haioun C, Itti E, Rahmouni A, et al. [18 F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.

    PubMed  CAS  Google Scholar 

  64. Lovisa F, Mussolin L, Corral L, et al. TCR-based RQ-PCR assay for MDD and MRD assessment in T-cell lymphoblastic lymphoma of childhood. Hematol Meeting Rep. 2009;3:37.

    Google Scholar 

  65. Coustan-Smith E, Sandlund JT, Perkins SL, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J Clin Oncol. 2009;27:3533–9.

    PubMed  Google Scholar 

  66. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev. 2008;8:380–90.

    CAS  Google Scholar 

  67. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.

    PubMed  CAS  Google Scholar 

  68. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–43.

    PubMed  CAS  Google Scholar 

  69. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica. 2005;90:1116–27.

    PubMed  Google Scholar 

  70. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143:153–68.

    PubMed  Google Scholar 

  71. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306–15.

    PubMed  CAS  Google Scholar 

  72. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–64.

    PubMed  CAS  Google Scholar 

  73. Teitell MA, Pandolfi PP. Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol. 2009;4:175–98.

    PubMed  CAS  Google Scholar 

  74. Begley CG, Aplan PD, Davey MP, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A. 1989;86:2031–5.

    PubMed  CAS  Google Scholar 

  75. Bernard O, Guglielmi P, Jonveaux P, et al. Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias. Genes Chromosomes Cancer. 1990;1:194–208.

    PubMed  CAS  Google Scholar 

  76. Chen Q, Cheng JT, Tasi LH, et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 1990;9:415–24.

    PubMed  CAS  Google Scholar 

  77. Xia Y, Brown L, Yang CY, et al. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc Natl Acad Sci U S A. 1991;88:11416–20.

    PubMed  CAS  Google Scholar 

  78. Mellentin JD, Smith SD, Cleary ML. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell. 1989;58:77–83.

    PubMed  CAS  Google Scholar 

  79. Wang J, Jani-Sait SN, Escalon EA, et al. The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic leukemia activates the BHLHB1 gene. Proc Natl Acad Sci U S A. 2000;97:3497–502.

    PubMed  CAS  Google Scholar 

  80. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A. 1991;88:4367–71.

    PubMed  CAS  Google Scholar 

  81. McGuire EA, Hockett RD, Pollock KM, Bartholdi MF, O’Brien SJ, Korsmeyer SJ. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol. 1989;9:2124–32.

    PubMed  CAS  Google Scholar 

  82. Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene. 1991;6:1887–93.

    PubMed  CAS  Google Scholar 

  83. Dube ID, Kamel-Reid S, Yuan CC, et al. A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood. 1991;78:2996–3003.

    PubMed  CAS  Google Scholar 

  84. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science. 1991;253:79–82.

    PubMed  CAS  Google Scholar 

  85. Kennedy MA, Gonzalez-Sarmiento R, Kees UR, et al. HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proc Natl Acad Sci U S A. 1991;88:8900–4.

    PubMed  CAS  Google Scholar 

  86. Lu M, Gong ZY, Shen WF, Ho AD. The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein. EMBO J. 1991;10:2905–10.

    PubMed  CAS  Google Scholar 

  87. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia. 2001;15:1495–504.

    PubMed  CAS  Google Scholar 

  88. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75–87.

    PubMed  CAS  Google Scholar 

  89. Przybylski GK, Dik WA, Grabarczyk P, et al. The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. Haematologica. 2006;91:317–21.

    PubMed  CAS  Google Scholar 

  90. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106:274–86.

    PubMed  CAS  Google Scholar 

  91. Speleman F, Cauwelier B, Dastugue N, et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia. 2005;19:358–66.

    PubMed  CAS  Google Scholar 

  92. Erikson J, Finger L, Sun L, et al. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science. 1986;232:884–6.

    PubMed  CAS  Google Scholar 

  93. Shima EA, Le Beau MM, McKeithan TW, et al. Gene encoding the alpha chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemia. Proc Natl Acad Sci U S A. 1986;83:3439–43.

    PubMed  CAS  Google Scholar 

  94. Clappier E, Cuccuini W, Kalota A, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 2007;110:1251–61.

    PubMed  CAS  Google Scholar 

  95. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593–5.

    PubMed  CAS  Google Scholar 

  96. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649–61.

    PubMed  CAS  Google Scholar 

  97. Rubnitz JE, Camitta BM, Mahmoud H, et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol. 1999;17:191–6.

    PubMed  CAS  Google Scholar 

  98. Bohlander SK, Muschinsky V, Schrader K, et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia. 2000;14:93–9.

    PubMed  CAS  Google Scholar 

  99. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008;111:4668–80.

    PubMed  Google Scholar 

  100. Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003;40:274–80.

    PubMed  CAS  Google Scholar 

  101. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol. 2000;1:138–44.

    PubMed  CAS  Google Scholar 

  102. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038–44.

    PubMed  CAS  Google Scholar 

  103. Tycko B, Smith SD, Sklar J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J Exp Med. 1991;174:867–73.

    PubMed  CAS  Google Scholar 

  104. Clappier E, Cuccuini W, Cayuela JM, et al. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 2006;20:82–6.

    PubMed  CAS  Google Scholar 

  105. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205:751–8.

    PubMed  CAS  Google Scholar 

  106. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309–12.

    PubMed  CAS  Google Scholar 

  107. Van Limbergen H, Beverloo HB, van Drunen E, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer. 2001;30:274–82.

    PubMed  Google Scholar 

  108. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36:1084–9.

    PubMed  CAS  Google Scholar 

  109. De Keersmaecker K, Graux C, Odero MD, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105:4849–52.

    PubMed  Google Scholar 

  110. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood. 2004;104:558–60.

    PubMed  CAS  Google Scholar 

  111. Van Vlierberghe P, Meijerink JP, Stam RW, et al. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood. 2005;106:4414–5.

    PubMed  Google Scholar 

  112. Bar-Eli M, Ahuja H, Foti A, Cline MJ. N-RAS mutations in T-cell acute lymphocytic leukaemia: analysis by direct sequencing detects a novel mutation. Br J Haematol. 1989;72:36–9.

    PubMed  CAS  Google Scholar 

  113. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;111:4322–8.

    PubMed  CAS  Google Scholar 

  114. Lo TC, Barnhill LM, Kim Y, Nakae EA, Yu AL, Diccianni MB. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res. 2009;33:1562–6.

    PubMed  CAS  Google Scholar 

  115. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13:1203–10.

    PubMed  CAS  Google Scholar 

  116. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood. 2009;114:1038–45.

    PubMed  CAS  Google Scholar 

  117. Sambandam A, Maillard I, Zediak VP, et al. Notch signaling controls the generation and differentiation of early T lineage progenitors. Nat Immunol. 2005;6:663–70.

    PubMed  CAS  Google Scholar 

  118. Radtke F, Ferrero I, Wilson A, Lees R, Aguet M, MacDonald HR. Notch1 deficiency dissociates the intrathymic development of dendritic cells and T cells. J Exp Med. 2000;191:1085–94.

    PubMed  CAS  Google Scholar 

  119. Radtke F, Wilson A, MacDonald HR. Notch signaling in T- and B-cell development. Curr Opin Immunol. 2004;16:174–9.

    PubMed  CAS  Google Scholar 

  120. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol. 2004;5:247–53.

    PubMed  CAS  Google Scholar 

  121. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17:749–56.

    PubMed  CAS  Google Scholar 

  122. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:347–59.

    PubMed  CAS  Google Scholar 

  123. Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103:18261–6.

    PubMed  CAS  Google Scholar 

  124. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20:2096–109.

    PubMed  CAS  Google Scholar 

  125. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996;183:2283–91.

    PubMed  CAS  Google Scholar 

  126. Sulis ML, Williams O, Palomero T, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112:733–40.

    PubMed  CAS  Google Scholar 

  127. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8:83–93.

    PubMed  CAS  Google Scholar 

  128. Malyukova A, Dohda T, von der Lehr N, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007;67:5611–6.

    PubMed  CAS  Google Scholar 

  129. O’Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813–24.

    PubMed  Google Scholar 

  130. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007;204:1825–35.

    PubMed  CAS  Google Scholar 

  131. Lewis HD, Leveridge M, Strack PR, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol. 2007;14:209–19.

    PubMed  CAS  Google Scholar 

  132. Deangelo D, Stone R, Silverman L, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006;24:6585.

    Google Scholar 

  133. Milano J, McKay J, Dagenais C, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341–58.

    PubMed  CAS  Google Scholar 

  134. van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959–63.

    PubMed  Google Scholar 

  135. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23:1374–7.

    PubMed  CAS  Google Scholar 

  136. Buonamici S, Trimarchi T, Ruocco MG, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009;459:1000–4.

    PubMed  CAS  Google Scholar 

  137. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–58.

    PubMed  CAS  Google Scholar 

  138. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.

    PubMed  CAS  Google Scholar 

  139. Tumours of haematopoietic and lymphoid tissues. In: Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization Classification of Tumors. Washington, DC: IARC Press; 2000.

    Google Scholar 

  140. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681–95.

    PubMed  CAS  Google Scholar 

  141. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623–37.

    PubMed  CAS  Google Scholar 

  142. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076–84.

    PubMed  CAS  Google Scholar 

  143. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.

    PubMed  CAS  Google Scholar 

  144. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697–706.

    PubMed  CAS  Google Scholar 

  145. Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61:2939–53.

    PubMed  CAS  Google Scholar 

  146. Murphy SB. Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol. 1994;5 Suppl 1:31–3.

    PubMed  Google Scholar 

  147. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14:219–28.

    PubMed  CAS  Google Scholar 

  148. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol. 2007;25:3915–22.

    PubMed  Google Scholar 

  149. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97:3699–706.

    PubMed  CAS  Google Scholar 

  150. Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12:895–8.

    PubMed  CAS  Google Scholar 

  151. Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591–8.

    PubMed  CAS  Google Scholar 

  152. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23:541–7.

    PubMed  CAS  Google Scholar 

  153. Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52:335–9.

    PubMed  Google Scholar 

  154. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104:2133–40.

    PubMed  CAS  Google Scholar 

  155. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117:812–20.

    PubMed  CAS  Google Scholar 

  156. Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53–8.

    PubMed  CAS  Google Scholar 

  157. Kraveka JM, Weitzman S, Smith L, et al. Advanced-stage anaplastic large-cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: a report from the Children’s Oncology Group. Hematol Meeting Rep. 2009;3:41.

    Google Scholar 

  158. Brugieres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897–903.

    PubMed  CAS  Google Scholar 

  159. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111:1560–6.

    PubMed  Google Scholar 

  160. Massimino M, Spreafico F, Luksch R, Giardini R. Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol. 2001;37:97–102.

    PubMed  CAS  Google Scholar 

  161. Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110:670–7.

    PubMed  CAS  Google Scholar 

  162. Mussolin L, Bonvini P, Ait-Tahar K, et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia. 2009;23:400–2.

    PubMed  CAS  Google Scholar 

  163. Lamant L, McCarthy K, d’Amore ESG, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large cell lymphoma (ALCL): results of the ALCL99 study. Hematol Meeting Rep. 2009;3:42.

    Google Scholar 

  164. Sandlund JT, Pui CH, Roberts WM, et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994;84:2467–71.

    PubMed  CAS  Google Scholar 

  165. Vecchi V, Burnelli R, Pileri S, et al. Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Med Pediatr Oncol. 1993;21:402–10.

    PubMed  CAS  Google Scholar 

  166. Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N. Large cell non-Hodgkin lymphoma of childhood: analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer. 2000;88:186–97.

    PubMed  CAS  Google Scholar 

  167. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994;12:899–908.

    PubMed  CAS  Google Scholar 

  168. Cesaro S, Pillon M, Visintin G, et al. Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series. Eur J Haematol. 2005;75:22–6.

    PubMed  CAS  Google Scholar 

  169. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133:176–82.

    PubMed  Google Scholar 

  170. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848–54.

    PubMed  CAS  Google Scholar 

  171. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171–9.

    PubMed  CAS  Google Scholar 

  172. Bartlett N, Forero-Torres A, Rosenblatt J, et al. Complete remissions with SGN-35 weekly dosing: a phase I dose-escalation study in relapsed/refractory Hodgkin lymphoma or systemic ALCL patients. J Clin Oncol. 2009;17:8500.

    Google Scholar 

  173. Younes A, Forero-Torres A, Bartlett NL, et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood. 2008;112:1006.

    Google Scholar 

  174. Galkin AV, Melnick JS, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007;104:270–5.

    PubMed  CAS  Google Scholar 

  175. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420:345–61.

    PubMed  CAS  Google Scholar 

  176. Cannella S, Santoro A, Bruno G, et al. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer. 2007;109:2566–71.

    PubMed  CAS  Google Scholar 

  177. Clementi R, Locatelli F, Dupre L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 2005;105:4424–8.

    PubMed  CAS  Google Scholar 

  178. Singh RR, Cho-Vega JH, Davuluri Y, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 2009;69:2550–8.

    PubMed  CAS  Google Scholar 

  179. Lim MS, Carlson ML, Crockett DK, et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood. 2009;114:1585–95.

    PubMed  CAS  Google Scholar 

  180. Lim MS, Elenitoba-Johnson KS. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics. 2006;5:1787–98.

    PubMed  CAS  Google Scholar 

  181. Lim M, Tygeson J, Seiler C, et al. Proteomic analysis of Denileukin Diftitox (Ontak) as a potential therapeutic agent for ALCL. Hematol Meeting Rep. 2009;3:44.

    Google Scholar 

  182. Miles RR, Cairo MS, Satwani P, et al. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children’s oncology group report. Br J Haematol. 2007;138:506–12.

    PubMed  CAS  Google Scholar 

  183. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res. 2002;62:1559–66.

    PubMed  CAS  Google Scholar 

  184. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61:2194–9.

    PubMed  CAS  Google Scholar 

  185. Windsor R, Stiller C, Webb D. Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer. 2008;50:784–7.

    PubMed  Google Scholar 

  186. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.

    Google Scholar 

  187. Rudiger T, Geissinger E, Muller-Hermelink HK. ‘Normal counterparts’ of nodal peripheral T-cell lymphoma. Hematol Oncol. 2006;24:175–80.

    PubMed  Google Scholar 

  188. Nelson M, Horsman DE, Weisenburger DD, et al. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. Br J Haematol. 2008;141:461–9.

    PubMed  CAS  Google Scholar 

  189. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164:1837–48.

    PubMed  CAS  Google Scholar 

  190. Martinez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19:2254–63.

    PubMed  CAS  Google Scholar 

  191. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560–70.

    PubMed  CAS  Google Scholar 

  192. Hutchison RE, Laver JH, Chang M, et al. Non-anaplastic peripheral T-cell lymphoma in childhood and adolescence: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;51:29–33.

    PubMed  Google Scholar 

  193. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 1998;92:76–82.

    PubMed  CAS  Google Scholar 

  194. Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007;21:201–16.

    PubMed  CAS  Google Scholar 

  195. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–75.

    PubMed  CAS  Google Scholar 

  196. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134:202–7.

    PubMed  Google Scholar 

  197. Paolo C, Lucia F, Anna D. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48:1496–501.

    PubMed  CAS  Google Scholar 

  198. Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.

    PubMed  CAS  Google Scholar 

  199. Mollee P, Lazarus HM, Lipton J. Why aren’t we performing more allografts for aggressive non-Hodgkin’s lymphoma? Bone Marrow Transplant. 2003;31:953–60.

    PubMed  CAS  Google Scholar 

  200. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172–6.

    PubMed  Google Scholar 

  201. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.

    PubMed  CAS  Google Scholar 

  202. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–7.

    PubMed  CAS  Google Scholar 

  203. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Canellos GP, Cheson BD. CALGB 59901: results of a phase II study of 506U78 in CTCL and PTCL. Blood. 2004;104:2486.

    Google Scholar 

  204. Piekarz R, Wright J, Frye R, et al. Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood (ASH Annual Meeting Abstracts). 2008;112:1567.

    Google Scholar 

  205. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol. 2008;19:396–7.

    PubMed  CAS  Google Scholar 

  206. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia. 2005;19:1993–5.

    PubMed  CAS  Google Scholar 

  207. O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27:4357–64.

    PubMed  Google Scholar 

  208. O’Connor OA, Pro B, Pinter-Brown L, et al. PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2008;112:261.

    Google Scholar 

  209. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058–65.

    PubMed  CAS  Google Scholar 

  210. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:4293–7.

    PubMed  CAS  Google Scholar 

  211. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 2008;19:2079–83.

    PubMed  CAS  Google Scholar 

  212. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–4.

    PubMed  CAS  Google Scholar 

  213. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1 H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–23.

    PubMed  CAS  Google Scholar 

  214. Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin’s lymphomas. Curr Opin Hematol. 2009;16:299–305.

    PubMed  CAS  Google Scholar 

  215. Horwitz SM. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2008;2008:289–96.

    Google Scholar 

  216. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7.

    PubMed  Google Scholar 

  217. Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood. 2009;113:1071–4.

    PubMed  CAS  Google Scholar 

  218. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13:359–72.

    PubMed  CAS  Google Scholar 

  219. Dahl GV, Rivera G, Pui CH, et al. A novel treatment of childhood lymphoblastic non-Hodgkin’s lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985;66:1110–4.

    PubMed  CAS  Google Scholar 

  220. Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol. 2001;19:1935–42.

    PubMed  CAS  Google Scholar 

  221. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol. 1983;1:537–41.

    PubMed  CAS  Google Scholar 

  222. Eden OB, Hann I, Imeson J, Cotterill S, Gerrard M, Pinkerton CR. Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children’s Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol. 1992;82:310–6.

    PubMed  CAS  Google Scholar 

  223. Abromowitch M, Sposto R, Perkins S, Finlay J, Cairo MS. Results of CCG-5941: intensified multiagent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents. Blood. 2006;108:533.

    Google Scholar 

  224. Adam P, Katzenberger T, Seeberger H, et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol. 2003;27:1473–6.

    PubMed  Google Scholar 

  225. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4.

    PubMed  CAS  Google Scholar 

  226. Onciu M, Behm FG, Downing JR, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003;102:2642–4.

    PubMed  CAS  Google Scholar 

  227. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954–60.

    PubMed  CAS  Google Scholar 

  228. Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999;93:3088–95.

    PubMed  CAS  Google Scholar 

  229. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157:377–84.

    PubMed  CAS  Google Scholar 

  230. Siebert R, Gesk S, Harder L, et al. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood. 1999;94:3614–7.

    PubMed  CAS  Google Scholar 

  231. Hernandez L, Bea S, Bellosillo B, et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol. 2002;160:1487–94.

    PubMed  CAS  Google Scholar 

  232. Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood. 1999;94:3265–8.

    PubMed  CAS  Google Scholar 

  233. Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol. 2000;156:781–9.

    PubMed  CAS  Google Scholar 

  234. Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood. 2000;95:2144–9.

    PubMed  CAS  Google Scholar 

  235. Trinei M, Lanfrancone L, Campo E, et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000;60:793–8.

    PubMed  CAS  Google Scholar 

  236. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159:411–5.

    PubMed  CAS  Google Scholar 

  237. Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol. 2007;20:310–9.

    PubMed  CAS  Google Scholar 

  238. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood. 2000;95:3204–7.

    PubMed  CAS  Google Scholar 

  239. Tort F, Campo E, Pohlman B, Hsi E. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol. 2004;35:1038–41.

    PubMed  CAS  Google Scholar 

  240. Tort F, Pinyol M, Pulford K, et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest. 2001;81:419–26.

    PubMed  CAS  Google Scholar 

  241. Meech SJ, McGavran L, Odom LF, et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4—anaplastic lymphoma kinase gene fusion. Blood. 2001;98:1209–16.

    PubMed  CAS  Google Scholar 

  242. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002;34:354–62.

    PubMed  CAS  Google Scholar 

  243. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003;37:98–105.

    PubMed  CAS  Google Scholar 

  244. Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003;37:427–32.

    PubMed  CAS  Google Scholar 

  245. Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest. 2003;83:1255–65.

    PubMed  CAS  Google Scholar 

  246. Stachurski D, Miron PM, Al-Homsi S, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22-24. Hum Pathol. 2007;38:940–5.

    PubMed  CAS  Google Scholar 

  247. Panagopoulos I, Nilsson T, Domanski HA, et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer. 2006;118:1181–6.

    PubMed  CAS  Google Scholar 

  248. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Columbia University, New York, NY, USA

    Nader Kim El-Mallawany

  2. Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA

    Pieter Van Vlierberghe

  3. Institute for Cancer Genetics, Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY, USA

    Adolfo A. Ferrando

  4. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

    Megan S. Lim

  5. Pediatric Hematology/Oncology/Stem Cell Transplantation, New York Medical College, 50 Plaza West, Munger Pavilion, Room 110A, Valhalla, NY, 10595, USA

    Mitchell S. Cairo

Authors
  1. Nader Kim El-Mallawany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieter Van Vlierberghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adolfo A. Ferrando
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megan S. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitchell S. Cairo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchell S. Cairo .

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, Dept. of Medical Oncology/Hematology, Cedar Street 333, New Haven, 06520, Connecticut, USA

    Francine Foss

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

El-Mallawany, N.K., Van Vlierberghe, P., Ferrando, A.A., Lim, M.S., Cairo, M.S. (2013). T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science. In: Foss, F. (eds) T-Cell Lymphomas. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-170-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-170-7_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-169-1

  • Online ISBN: 978-1-62703-170-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation